Our Science – Cheng Website
Sheue-yann Cheng, Ph.D.
Selected Publications |
 |
| 1)
Fozzatti L, Kim DW, Park JW, Willingham MC, Hollenberg AN, Cheng SY. Nuclear receptor corepressor (NCOR1) regulates in vivo actions of a mutated thyroid hormone receptor a. Proc. Natl. Acad. Sci. U.S.A. 2013. [Journal] |
|
| 2)
Kim WG, Zhu X, Kim DW, Zhang L, Kebebew E, Cheng S. Reactivation of the silenced thyroid hormone receptor beta gene expression delays thyroid tumor progression. Endocrinology. 154: 25-35, 2013. [Journal] |
|
| 3)
Blank M, Tang Y, Yamashita M, Burkett SS, Cheng SY, Zhang YE. A tumor suppressor function of Smurf2 associated with controlling chromatin landscape and genome stability through RNF20. Nat. Med. 18: 227-34, 2012. [Journal] |
|
| 4)
Ward Y, Lake R, Martin PL, Killian K, Salerno P, Wang T, Meltzer P, Merino M, Cheng S, Santoro M, Garcia-Rostan G, Kelly K. CD97 amplifies LPA receptor signaling and promotes thyroid cancer progression in a mouse model. Oncogene. [Epub ahead of print], 2012. [Journal] |
|
| 5)
Zhao L, Zhu X, Won Park J, Fozzatti L, Willingham M, Cheng S. Role of TSH in the spontaneous development of asymmetrical thyroid carcinoma in mice with a targeted mutation in a single allele of the thyroid hormone-beta receptor. Endocrinology. 153: 5090-100, 2012. [Journal] |
|
| 6)
Kim DW, Zhao L, Hanover J, Willingham M, Cheng S. Thyroid hormone receptor beta suppresses SV40-mediated tumorigenesis via novel nongenomic actions. Am J Cancer Res. 2: 606-19, 2012. [Journal] |
|
| 7)
Lu C, Zhu X, Willingham MC, Cheng SY. Activation of tumor cell proliferation by thyroid hormone in a mouse model of follicular thyroid carcinoma. Oncogene. 31: 2007-16, 2012. [Journal] |
|
| 8)
O'Shea PJ, Kim DW, Logan JG, Davis S, Walker RL, Meltzer PS, Cheng S, Williams GR. Advanced Bone Formation in Mice with a Dominant-negative Mutation in the Thyroid Hormone Receptor Beta Gene due to Activation of Wnt/beta-Catenin Protein Signaling. J. Biol. Chem. 287: 17812-22, 2012. [Journal] |
|
| 9)
Zhu X, Cheng SY. Modeling follicular thyroid cancer for future therapies. Am J Cancer Res. 2: 130-40, 2012. [Journal] |
|
| 10)
Kim WG, Guigon CJ, Fozzatti L, Park JW, Lu C, Willingham MC, Cheng SY. SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer. Clin. Cancer Res. 18: 1281-90, 2012. [Journal] |
|
| 11)
Chocron ES, Sayre NL, Holstein D, Saelim N, Ibdah JA, Dong LQ, Zhu X, Cheng S, Lechleiter JD. The Trifunctional Protein Mediates Thyroid Hormone Receptor-Dependent Stimulation of Mitochondria Metabolism. Mol Endocrinol. 26: 1117-28, 2012. [Journal] |
|
| 12)
Kim WG, Cheng S. Thyroid hormone receptors and cancer. Biochim Biophys Acta. [Epub ahead of print], 2012. [Journal] |
|
| 13)
Cordas EA, Ng L, Hernandez A, Kaneshige M, Cheng SY, Forrest D. Thyroid hormone receptors control developmental maturation of the middle ear and the size of the ossicular bones. Endocrinology. 153: 1548-60, 2012. [Journal] |
|
| 14)
Sinha RA, You SH, Zhou J, Siddique MM, Bay BH, Zhu X, Privalsky ML, Cheng SY, Stevens RD, Summers SA, Newgard CB, Lazar MA, Yen PM. Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy. J. Clin. Invest. 122: 2428-38, 2012. [Journal] |
|
| 15)
Fozzatti L, Lu C, Kim DW, Cheng SY. Differential recruitment of nuclear coregulators directs the isoform-dependent action of mutant thyroid hormone receptors. Mol. Endocrinol. 25: 908-21, 2011. [Journal] |
|
| 16)
Lu C, Cheng S. Extranuclear signaling of mutated thyroid hormone receptors in promoting metastatic spread in thyroid carcinogenesis. Steroids. 76: 885-91, 2011. [Journal] |
|
| 17)
Lu C, Mishra A, Zhu YJ, Meltzer P, Cheng S. Genomic profiling of genes contributing to metastasis in a mouse model of thyroid follicular carcinoma. Am J Cancer Res. 1: 1-13, 2011. [Journal] |
|
| 18)
Lu C, Mishra A, Zhu YJ, Meltzer P, Cheng S. Global expression profiling reveals gain-of-function oncogenic activity of a mutated thyroid hormone receptor in thyroid carcinogenesis. Am J Cancer Res. 1: 168-191, 2011. [Journal] |
|
| 19)
Guigon CJ, Kim DW, Willingham MC, Cheng S. Mutation of thyroid hormone receptor-beta in mice predisposes to the development of mammary tumors. Oncogene. 30: 3381-90, 2011. [Journal] |
|
| 20)
Zhu X, Kim D, Goodson M, Privalsky ML, Cheng S. NCoR1 Regulates Thyroid Hormone Receptor Isoform-dependent Adipogenesis. J Mol Endocrinol. 46: 233-44, 2011. [Journal] |
|
| 21)
Fozzatti L, Lu C, Kim DW, Park JW, Astapova I, Gavrilova O, Willingham MC, Hollenberg AN, Cheng SY. Resistance to thyroid hormone is modulated in vivo by the nuclear receptor corepressor (NCOR1). Proc. Natl. Acad. Sci. U.S.A. 108: 17462-7, 2011. [Journal] |
|
| 22)
Mishra A, Zhu XG, Ge K, Cheng SY. Adipogenesis is differentially impaired by thyroid hormone receptor mutant isoforms. J. Mol. Endocrinol. 44: 247-55, 2010. [Journal] |
|
| 23)
Ribeiro MO, Bianco SD, Kaneshige M, Schultz JJ, Cheng SY, Bianco AC, Brent GA. Expression of uncoupling protein 1 in mouse brown adipose tissue is thyroid hormone receptor-beta isoform specific and required for adaptive thermogenesis. Endocrinology. 151: 432-40, 2010. [Journal] |
|
| 24)
Lu C, Zhao L, Ying H, Willingham MC, Cheng SY. Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma. Endocrinology. 151: 1929-39, 2010. [Journal] |
|
| 25)
Guigon CJ, Fozzatti L, Lu C, Willingham MC, Cheng SY. Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer. Carcinogenesis. 31: 1284-91, 2010. [Journal] |
|
| 26)
Cheng SY, Leonard JL, Davis PJ. Molecular aspects of thyroid hormone actions. Endocr. Rev. 31: 139-70, 2010. [Journal] |
|
| 27)
Zhu X, Cheng SY. New insights into regulation of lipid metabolism by thyroid hormone. Current opinion in endocrinology, diabetes, and obesity. 2010. [Journal] |
|
| 28)
Huang Y, Guigon CJ, Fan J, Cheng SY, Zhu GZ. Pituitary homeobox 2 (PITX2) promotes thyroid carcinogenesis by activation of cyclin D2. Cell cycle (Georgetown, Tex.). 9, 2010. [Journal] |
|
| 29)
Zhu XG, Zhao L, Willingham MC, Cheng SY. Thyroid hormone receptors are tumor suppressors in a mouse model of metastatic follicular thyroid carcinoma. Oncogene. 29: 1909-19, 2010. [Journal] |
|
| 30)
Lu C, Cheng SY. Thyroid hormone receptors regulate adipogenesis and carcinogenesis via crosstalk signaling with peroxisome proliferator-activated receptors. J. Mol. Endocrinol. 44: 143-54, 2010. [Journal] |
|
| 31)
Guigon CJ, Kim DW, Zhu X, Zhao L, Cheng SY. Tumor suppressor action of liganded thyroid hormone receptor beta by direct repression of beta-catenin gene expression. Endocrinology. 151: 5528-36, 2010. [Journal] |
|
| 32)
Araki O, Ying H, Zhu XG, Willingham MC, Cheng SY. Distinct dysregulation of lipid metabolism by unliganded thyroid hormone receptor isoforms. Mol. Endocrinol. 23: 308-15, 2009. [Journal] |
|
| 33)
Cheng SY, Ringel MD. Frontiers in thyroid cancer: December 2009. Thyroid. 19: 1297-8, 2009. [Journal] |
|
| 34)
Zhu XG, Cheng SY. Modeling thyroid cancer in the mouse. Horm. Metab. Res. 41: 488-99, 2009. [Journal] |
|
| 35)
Furuya F, Lu C, Guigon CJ, Cheng SY. Nongenomic activation of phosphatidylinositol 3-kinase signaling by thyroid hormone receptors. Steroids. 74: 628-34, 2009. [Journal] |
|
| 36)
Guigon CJ, Cheng SY. Novel non-genomic signaling of thyroid hormone receptors in thyroid carcinogenesis. Mol. Cell. Endocrinol. 308: 63-9, 2009. [Journal] |
|
| 37)
Guigon CJ, Cheng SY. Novel oncogenic actions of TRbeta mutants in tumorigenesis. IUBMB Life. 61: 528-36, 2009. [Journal] |
|
| 38)
Guigon CJ, Zhao L, Willingham MC, Cheng SY. PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer. Oncogene. 28: 509-17, 2009. [Journal] |
|
| 39)
Lu C, Willingham MC, Furuya F, Cheng SY. Activation of phosphatidylinositol 3-kinase signaling promotes aberrant pituitary growth in a mouse model of thyroid-stimulating hormone-secreting pituitary tumors. Endocrinology. 149: 3339-45, 2008. [Journal] |
|
| 40)
Guigon CJ, Zhao L, Lu C, Willingham MC, Cheng SY. Regulation of beta-catenin by a novel nongenomic action of thyroid hormone beta receptor. Mol. Cell. Biol. 28: 4598-608, 2008. [Journal] |
|
| 41)
Nofsinger RR, Li P, Hong SH, Jonker JW, Barish GD, Ying H, Cheng SY, Leblanc M, Xu W, Pei L, Kang YJ, Nelson M, Downes M, Yu RT, Olefsky JM, Lee CH, Evans RM. SMRT repression of nuclear receptors controls the adipogenic set point and metabolic homeostasis. Proc. Natl. Acad. Sci. U.S.A. 105: 20021-6, 2008. [Journal] |
|
| 42)
Glogowska A, Pyka J, Kehlen A, Los M, Perumal P, Weber E, Cheng SY, Hoang-Vu C, Klonisch T. The cytoplasmic domain of proEGF negatively regulates motility and elastinolytic activity in thyroid carcinoma cells. Neoplasia. 10: 1120-30, 2008. [Journal] |
|
| 43)
Ying H, Willingham MC, Cheng SY. The steroid receptor coactivator-3 is a tumor promoter in a mouse model of thyroid cancer. Oncogene. 27: 823-30, 2008. [Journal] |
|
| 44)
Owen PJ, Ying H, Lang D, Tomlinson D, Lewis MJ, Cheng SY, Lazarus JH. Endothelial dysfunction in a murine model of thyroid hormone resistance. Eur. J. Clin. Invest. 37: 390-5, 2007. [Journal] |
|
| 45)
Kim CS, Furuya F, Ying H, Kato Y, Hanover JA, Cheng SY. Gelsolin: a novel thyroid hormone receptor-beta interacting protein that modulates tumor progression in a mouse model of follicular thyroid cancer. Endocrinology. 148: 1306-12, 2007. [Journal] |
|
| 46)
Ying H, Araki O, Furuya F, Kato Y, Cheng SY. Impaired adipogenesis caused by a mutated thyroid hormone alpha1 receptor. Mol. Cell. Biol. 27: 2359-71, 2007. [Journal] |
|
| 47)
Furuya F, Lu C, Willingham MC, Cheng S. Inhibition of phosphatidylinositol 3' kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer. Carcinogenesis. 28: 2451-8, 2007. [Journal] |
|
| 48)
Cheng S. Mutations of thyroid hormone nuclear receptors and disease. Frontiers in Science. 5: 11-14, 2007. [Journal] |
|
| 49)
Furuya F, Ying H, Zhao L, Cheng SY. Novel functions of thyroid hormone receptor mutants: beyond nucleus-initiated transcription. Steroids. 72: 171-9, 2007. [Journal] |
|
| 50)
Furuya F, Guigon C, Zhao L, Lu C, Hanover JA, Cheng S. Nuclear receptor corepressor (NCoR) is a novel regulator of PI3K signaling. Mol Cell Biol. 27: 6116-26, 2007. [Journal] |
|
| 51)
O'Shea PJ, Guigon CJ, Williams GR, Cheng S. Regulation of Fibroblast Growth Factor Receptor-1 by Thyroid Hormone: Identification of a Thyroid Hormone Response Element in the Murine Fgfr1 Promoter. Endocrinology. 148: 5966-76, 2007. [Journal] |
|
| 52)
Pemberton HN, Franklyn JA, Boelaert K, Chan SY, Kim DS, Kim C, Cheng SY, Kilby MD, McCabe CJ. Separase, securin and Rad21 in neural cell growth. J Cell Physiol. 213: 45-53, 2007. [Journal] |
|
| 53)
Kim CS, Ying H, Willingham MC, Cheng SY. The pituitary tumor-transforming gene promotes angiogenesis in a mouse model of follicular thyroid cancer. Carcinogenesis. 28: 932-9, 2007. [Journal] |
|
| 54)
Cheng S. Thyroid hormone receptor mutations and disease: insights from knockin mouse models. Expert Rev Endocrinol Metab. 2: 47-57, 2007. [Journal] |
|
| Click Here to View Collapsed Bibliography. |
This page was last updated on 5/6/2013.
